This study is not yet accepting patients
Vactosertib With Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UCSF
- Dates
- study startedcompletion around
- Principal Investigator
- by Lawrence Fong, MD (ucsf)
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at University of California Health
- Lawrence Fong, MD (ucsf)
Details
- Status
- not yet accepting patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- MedPacto, Inc.
- ID
- NCT04064190
- Phase
- Phase 2 research study
- Study Type
- Interventional
- Participants
- Expecting 48 study participants
- Last Updated